0TDD

Novo Nordisk A/S Sponsored ADR Class B · LSE:0TDD

39.71 USD−0.1814 −0.45%

Novo Nordisk A/S Sponsored ADR Class B (LSE:0TDD) last traded at 39.71 USD, down 0.45% on the day. Over the past year the stock is down 20.93%. Its 52-week range is 35.14 to 64.44. It is in the Health Technology sector (Pharmaceuticals: Major).

Key statistics

Open40.03

Day range39.67 – 40.03

52-week range35.14 – 64.44

Volume2.21 K

Average volume (10 days)60.70 K

Market cap175.64 B

P/E9.70

EPS (TTM)4.09

Dividend yield3.08%

Beta (1 year)0.2429

Revenue (TTM)51.45 B

Employees68.79 K

Performance

+1.46%1 week

+5.98%1 month

−16.11%3 months

−15.48%6 months

−22.71%Year to date

−20.93%1 year

Technical reading

Neutral

Daily summary of what 11 oscillators and 15 moving averages show. See every indicator

Latest headlines

Weekly Recap: Wegovy scripts 265k+ and injunction denied in Eli Lilly ad suitTradingView · 02 Nov 2026
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026

Market data from TradingView’s public feed, delayed as the exchange requires. SuperCharting is charting software and gives no investment advice.